In 2017, the Top 5 Vaccines Manufacturers held 76% of the Global Vaccines Market

Monday 25 February 2019, Amsterdam

The world vaccines market is set to grow steadily over the next 10 years. This growth is mainly driven by a global ageing population, as the elderly are more prone to contracting infections due to their pre-existing health conditions and a weak immune system. Demand from the emerging markets further drive growth as their middle class gets wealthier and demand better healthcare systems, furthermore the high birth rates in the emerging markets will feed the paediatric vaccines segment. Moreover, the vaccine industry benefits from strong research and development leading to continuous innovation. Technological advancements will be made in vaccine delivery and administration. As a result, the development of more efficient technology will reduce costs of vaccine production, making the entire manufacturing and supply chain more efficient.

The lead analyst of the report commented "Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development. New target sites, ways of generating an immune response and method of administration are already being investigated and, in some cases, successfully implemented. Further progress is expected to be made in this field as companies look for other ways to gain a competitive edge over their rivals, which could just be another way of administering an existing vaccine. This factor is expected to provide strong growth opportunities to vaccines manufacturers."

Leading companies featured in the report include Astellas Pharma Inc., AstraZeneca, Bavarian, Nordic, CSL Ltd., Emergent Biosolutions, Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences, GlaxoSmithKline PLC, Inovio Pharmaceuticals and others.